title: Enhancement of serum lipoprotein lipase mass levels by intensive insulin therapy.
abstract: We previously reported that lipoprotein lipase mass level in preheparin serum (preheparin LPL mass) was significantly lower in type 2 diabetes mellitus compared to healthy subjects and increased by conventional insulin therapy using NPH (intermediate-acting) insulin. The aim of this study was to investigate the effects of intensive insulin therapy on preheparin LPL mass. Thirty-two subjects (total group) with type 2 diabetes receiving treatment by NPH insulin injection twice a day in the morning and evening were switched to basal bolus insulin (BBI) therapy (fast-acting insulin after each meal and NPH insulin before bedtime). In 14 subjects, the total daily insulin dose was not change after switching to BBI therapy (iso-dose group). After 3 months of BBI therapy, preheparin LPL mass increased significantly from 47 to 56 ng/ml in total group. Glycosylated hemoglobin and serum triglyceride levels decreased significantly, and high-density lipoprotein-cholesterol increased significantly. Low-density lipoprotein levels did not changed but increase in size was suggested by PAG disc electrophoresis. Similar changes were observed in the iso-dose group. These results suggest that BBI therapy enhances preheparin LPL mass, accompanied by antiatherogenic changes in glucose and lipid metabolism.
authors.affiliation: Department of Internal Medicine, Sakura Hospital, School of Medicine, Toho University, 564-1 Shimoshizu, Sakura-City, Chiba 285-0841, Japan. mumon@sf6.so-net.ne.jp
authors.forename: Yoh
authors.initials: Y
authors.lastname: Miyashita
authors.forename: Mariko
authors.initials: M
authors.lastname: Ebisuno
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ohhira
authors.forename: Kei
authors.initials: K
authors.lastname: Endoh
authors.forename: Atsuhito
authors.initials: A
authors.lastname: Saiki
authors.forename: Nobukiyo
authors.initials: N
authors.lastname: Koide
authors.forename: Masaki
authors.initials: M
authors.lastname: Ohtsuka
authors.forename: Tomokazu
authors.initials: T
authors.lastname: Oyama
authors.forename: Kohji
authors.initials: K
authors.lastname: Shirai
mesh_terms: D015992:Body Mass Index; D001835:Body Weight; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy / Q000201:enzymology; D004334:Drug Administration Schedule; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007336:Insulin, Isophane / Q000008:administration & dosage / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008071:Lipoprotein Lipase / Q000097:blood*; D008297:Male; D008875:Middle Aged
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007336:Insulin, Isophane; D008055:Lipids; D008071:Lipoprotein Lipase